Molecular Diagnosis & Therapy · 2016 · 27 citations · 24 references
MedicineCancer BiologyOncologyMolecular OncologyNeoplasiaOral OncologyCancer BiomarkersMolecular Tumor ProfilingOral Cancer BiomarkersOral Cancer PrognosisOral Cavity CancerSquamous Cell CarcinomaHuman Papillomavirus StatusMolecular Prognostic MarkersOral Cavity PathologyPrognostic Tumor MarkersProtein Expression BiomarkersSquamous Cell Carcinoma PathologyTissue Microarrays
INTRODUCTION: Fibroblast growth factor receptor family member proteins (FGFR1-4) have been identified as promising novel therapeutic targets and prognostic markers in a wide spectrum of solid tumors. The present study investigates the expression and prognostic value of four FGFR family member proteins in a large multicenter oral cavity squamous cell carcinoma (OCSCC) and oropharyngeal squamous cell carcinoma (OPSCC) cohort. METHODS: Protein expression of FGFR1-4 was determined by immunohistochemistry on tissue microarrays containing 951 formalin-fixed paraffin embedded OCSCC and OPSCC tissues from the University Medical Center Utrecht and University Medical Center Groningen. Protein expression was correlated to overall survival using Cox regression models, and bootstrapping was performed as internal validation. RESULTS: FGFR proteins were highly expressed in 39-64 % of OCSCC and 63-79 % of OPSCC. Seventy-three percent (299/412) of OCSCC and 85 % (305/357) of OPSCC highly co-expressed two or more FGFR family member proteins. FGFR1 protein was more frequently highly expressed in human papillomavirus (HPV)-negative OPSCC than HPV-positive OPSCC (82 vs. 65 %; p = 0.008). Furthermore, protein expression of FGFR family members was not related to overall survival in OCSCC or OPSCC (p > 0.05). CONCLUSION: FGFR family members are frequently highly expressed in OCSCC and OPSCC. These FGFR family member proteins are therefore potential targets for novel therapies that are urgently required to improve survival of OCSCC and OPSCC patients.
24
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
Fabrice André, Thomas Bachelot, Mario Campone et al. · Clinical Cancer Research · 2013 · 313 citations
Medicine, Oncology, Pharmacology +14